BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Neuland Labs Announces ₹342-Crore Investment in Telangana Expansion

Synopsis:

Neuland Laboratories Ltd commits ₹342 crore for Telangana unit expansions, enhancing peptide capacity from 0.5 KL to 6.37 KL and reactor capacity to 373 KL, supporting growth in generic drugs and CMS.

Neuland Laboratories Ltd news today

Neuland Laboratories Ltd has announced a ₹342-crore capital investment to expand its manufacturing facilities in Telangana. The investment focuses on increasing capacity at its Bonthapally (Unit 1) and Gaddapotharam (Unit 3) facilities, aimed at bolstering the company’s peptide synthesiser and reactor capabilities.

Also read: Crude Oil Prices Slip Amid Trump’s Tariff Threats and Trade Fears

NEULAND LAB LTD.

Trade

12300-779.00 (-5.95 %)

Updated - 25 April 2025
13220.00day high
DAY HIGH
12200.00day low
DAY LOW
51071
VOLUME (BSE)

Key Takeaways

  • Total Investment: ₹342 crore for Telangana expansions.

  • Unit 1: ₹254 crore for peptide capacity increase (0.5 KL to 6.37 KL).

  • Unit 3: ₹88 crore for reactor capacity (321 KL to 373 KL).

  • Funding: Combination of debt and internal accruals.

  • Timeline: Unit 1 by FY27; Unit 3 in 15-18 months.

Also read: RailTel Secures ₹46.79 Crore Signalling Project with North Western Railway

Investment Details by Unit

Facility

Project

Investment (₹ Crore)

Capacity Increase

Timeline

Funding

Unit 1 (Bonthapally)

Peptide Synthesiser Expansion

₹254

0.5 KL to 6.37 KL

By FY27

Debt and internal accruals

Unit 3 (Gaddapotharam)

Reactor Capacity Expansion

₹88

321 KL to 373 KL

15-18 months

Internal accruals

Enhancing Peptide and Reactor Capacities

The expansion at Unit 1 will focus on building a new peptide manufacturing block to scale production for generic drug substances (GDS) and custom manufacturing solutions (CMS). This will support the growing demand for peptides in the pharmaceutical industry.

Unit 3’s reactor capacity increase will enhance production volumes to meet the company’s operational requirements efficiently. Both projects align with Neuland’s growth strategy to strengthen its position in the global pharmaceutical market.

Financial and Market Implications

Neuland Laboratories Ltd aims to fund the ₹342-crore investment through internal accruals and borrowings, showcasing its financial planning. However, Neuland Laboratories Ltd share price dropped 4.56% on BSE, closing at ₹13,196.05 on January 21. This reflects market reactions to the capital expenditure announcement, possibly influenced by its funding strategy.

The ₹342-crore expansion by Neuland Laboratories Ltd in Telangana underscores its focus on innovation and capacity enhancement, ensuring future growth in the generic drug and CMS sectors. Investors will closely monitor the progress of these projects and their potential impact on Neuland Laboratories Ltd share price.

Also read: JSW Group Signs ₹3-Lakh Crore MoU with Maharashtra for Green Investments

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text